FONO Series: Prostate Cancer (Part I & II)
3 CEs (.5 rx) Approved by AANP & CONO
If you have taken a CE quiz with OncANP before, you can sign in with the login you previously created. If you are logging in for the first time, please press the “register me” button and create an account.
Daniel Lander, ND, FABNO
Speaker Biography:
As a Fellow of the American Board of Naturopathic Oncology (FABNO), Daniel Lander is a Naturopathic Doctor with board certification in naturopathic oncology. He is a graduate of the Canadian College of Naturopathic Medicine (CCNM) and also holds a Bachelor of Science degree in Nutritional Sciences from the University of Guelph. His clinical training included a hospital-based integrative oncology residency at the Cancer Treatment Centers of America. He is currently an associate professor at CCNM and the director of the CCNM Integrative Cancer Centre. He is a past member of the OncANP Board of Directors and is currently serving his second term on the Board of Directors of the ABNO.
Abstract:
This lecture is designed to inform naturopathic doctors about the fundamental aspects of integrative naturopathic support for people with prostate cancer. This presentation will provide an overview of prostate cancer risk, diagnosis, staging, and the conventional treatment options. Most of the time will be spent reviewing the research on the safety and efficacy of dietary and lifestyle interventions and various integrative therapies which can be used alongside standard treatment in people with prostate cancer.
Learning Objectives:
Understand the etiology, diagnostic classifications, and natural history of prostate cancer.
Understand the various types of therapies used in the standard of care conventional management of prostate cancer, including the mechanisms of action and common adverse effects.
Become familiar with the available research on the safety and efficacy of dietary and lifestyle interventions and integrative therapies used in the naturopathic integrative management of people with prostate cancer.
Identify some potential important contraindications in the integrative management of people with prostate cancer.